Helus Pharma Inc.
Helus Pharma (HELP) announced updates on its mental health drug programs. HLP003 Phase 3 data readout is on track for Q4 2026, with FDA Breakthrough Therapy Designation. HLP004 Phase 2 monotherapy study for GAD is expected to start in Q1 2027, enrolling 144 adults. The company aims for FDA filing in 2028.
Cybin (NASDAQ: HELP) expects Q4 Phase III data for its depression treatment HLP003, which showed significant symptom improvement in earlier studies. The company also plans a Phase II study for its anxiety treatment HLP004 in 2027. HLP003 has FDA Breakthrough Therapy designation, and Cybin aims for comparable efficacy and favorable tolerability.
Helus Pharma Inc.'s average stock price target increased from $40.77 to $43.62, according to 9 analysts, with a potential 299% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 10 analysts.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HELP (Helus Pharma Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent HELP coverage spans financial news, insider activity and corporate actions.
In the last 30 days, HELP insiders filed 1 SEC Form 4 transaction — 1 purchase ($39K) and no sales. The most active reporter was Cavers Greg, Chief Financial Officer, with 1 filing.
The upcoming trial adds a near‑term catalyst that could move HELP shares depending on enrollment and early data.
Upcoming trial data could drive significant price movement depending on efficacy outcomes.
Helus Pharma Inc.'s average stock price target increased from $40.77 to $43.62, according to 9 analysts, with a potential 299% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 10 analysts.
Board appointment adds governance expertise; modest positive sentiment.
Insider purchase may signal confidence, creating modest upward pressure.
AlphAI scores every news story that mentions HELP with an AI model for sentiment and relevance, and aggregates insider trades from Helus Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Helus Pharma (HELP) announced updates on its mental health drug programs. HLP003 Phase 3 data readout is on track for Q4 2026, with FDA Breakthrough Therapy Designation. HLP004 Phase 2 monotherapy study for GAD is expected to start in Q1 2027, enrolling 144 adults. The company aims for FDA filing in 2028.
2 min readCybin (NASDAQ: HELP) expects Q4 Phase III data for its depression treatment HLP003, which showed significant symptom improvement in earlier studies. The company also plans a Phase II study for its anxiety treatment HLP004 in 2027. HLP003 has FDA Breakthrough Therapy designation, and Cybin aims for comparable efficacy and favorable tolerability.
2 min readHelus Pharma Inc.'s average stock price target increased from $40.77 to $43.62, according to 9 analysts, with a potential 299% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 10 analysts.
1 min readHelus Pharma (HELP) appointed Dr. Suresh Durgam to its Board, pending Cboe Canada approval. He previously served as CMO at Intra-Cellular Therapies and secured multiple FDA approvals. The company is advancing late-stage CNS programs, including a Phase 3 asset with Breakthrough Therapy Designation.
1 min readCavers Greg (Chief Financial Officer) purchased 3,000 indirectly-held shares of Helus Pharma Inc. (HELP) at $12.91 on 2026-09-29.
1 min readCybin Inc. has legally changed its name to Helus Pharma Inc. The rebrand, approved by shareholders, reflects the company's transition to a commercial-ready pharmaceutical firm. Shares will continue trading on Nasdaq and Cboe Canada under the ticker HELP. The company is developing serotonergic agonists for mental health disorders, with HLP003 in Phase 3 trials for major depressive disorder.
1 min readInsiders traded shares in five companies: Nutanix's president sold $4.76M shares, Star Bulk directors sold $435.82K, Berkshire Hathaway bought $348.78M Lennar shares, Hershey Trust sold $5.05M, and Helus Pharma's CEO bought $1.35M.
2 min readCybin Inc. shareholders voted on a name change to Helus Pharma, which requires two-thirds support. The company nominated eight directors, including CEO Michael Halstead. Voting results will be published post-meeting. Cybin focuses on psychedelic-based therapeutics for mental health conditions, with programs like CYB003 and CYB004.
1 min readAnalysts from Barclays and Bank of America updated ratings for healthcare companies. Helus Pharma (HELP) and Ultragenyx Pharmaceutical (RARE) both received Buy ratings with $35 price targets. Novavax (NVAX) was rated Sell with a $7 target. Current prices and analyst consensus targets were also provided.
2 min readHalstead Michael (Chief Executive Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $13.47 ($1.35M total) on 2026-09-21.
1 min read
